<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR46">
 <label>46.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kirouac</surname>
    <given-names>DC</given-names>
   </name>
   <name>
    <surname>Du</surname>
    <given-names>JY</given-names>
   </name>
   <name>
    <surname>Lahdenranta</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Overland</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Yarar</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Paragas</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Pace</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>McDonagh</surname>
    <given-names>CF</given-names>
   </name>
   <name>
    <surname>Nielsen</surname>
    <given-names>UB</given-names>
   </name>
   <name>
    <surname>Onsum</surname>
    <given-names>MD</given-names>
   </name>
  </person-group>
  <article-title>Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors</article-title>
  <source>Sci Signal</source>
  <year>2013</year>
  <volume>6</volume>
  <fpage>ra68</fpage>
  <pub-id pub-id-type="doi">10.1126/scisignal.2004008</pub-id>
  <?supplied-pmid 23943608?>
  <pub-id pub-id-type="pmid">23943608</pub-id>
 </element-citation>
</ref>
